IN-SITU ANALYSIS OF CELLULAR PROLIFERATION IN CANINE, FELINE AND EQUINE TUMORS BY IMMUNOHISTOCHEMISTRY - A COMPARISON OF BROMODEOXYURIDINE,PROLIFERATING CELL NUCLEAR ANTIGEN, AND INTERCHROMATIN-ASSOCIATED ANTIGEN IMMUNOSTAINING TECHNIQUES
Ap. Theon et al., IN-SITU ANALYSIS OF CELLULAR PROLIFERATION IN CANINE, FELINE AND EQUINE TUMORS BY IMMUNOHISTOCHEMISTRY - A COMPARISON OF BROMODEOXYURIDINE,PROLIFERATING CELL NUCLEAR ANTIGEN, AND INTERCHROMATIN-ASSOCIATED ANTIGEN IMMUNOSTAINING TECHNIQUES, Journal of veterinary diagnostic investigation, 6(4), 1994, pp. 453-457
Cell proliferation in canine, feline, and equine tumors was evaluated
using immunohistochemical detection of in vitro 5-bromodeoxyuridine (B
rdU) incorporation, proliferating cell nuclear antigen (PCNA), and int
erchromatin-associated antigen (p105). Ten tumors in each species were
analyzed. The tumor proliferative fraction (PF) was defined as the pe
rcentage of labeled nuclei for 5,000 tumor nuclei counted. Immunoreact
ivity was observed with all techniques in all species. A good correlat
ion was observed between the proliferative fractions measured with the
BrdU (PF(BrdU)) and PCNA (PF(PCNA)) techniques (r(s) = 0.523, P = 0.0
026). There was no correlation between the PFs measured with the BrdU
(PF(BrdU)) and p105 (PF(P105)) techniques. Using the median values obt
ained from the different approaches as cutoff points to define slowly
and rapidly proliferating tumors, there was an 80% agreement (P = 0.00
9) between PF(BrdU) and PF(PCNA) and no agreement between PF(BrdU) and
PF(P105). The results of this study indicate that both BrdU and PCNA
labeling methods can be used reliably for identifying proliferating ce
lls in animal tumors. In addition, PCNA could be used to replace the B
rdU method to assess tumor proliferative fraction because it does not
require pretreatment of tissues.